Proto Labs (PRLB) Stock Stalls As Record Growth Meets 69.3x P\E

Proto Labs stock barely moved today, slipping just 0.1% to around US$75 even after what was billed as another record quarter. The market reaction looks muted next to adjusted earnings per share of US$0.60 and double digit revenue growth in a manufacturing business that usually moves in smaller increments. For short term traders, the lack of a price pop might feel underwhelming. Long term investors are more likely to focus on the bigger issue: a P/E of 69.3x now sits on top of this earnings run, and that valuation question will not go away quickly.

Love the record Proto Labs earnings print but concerned about paying 69x earnings for it? Check out the 55 high quality undervalued stocks for ideas that pair solid fundamentals with less demanding valuations.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$149.3m vs. US$135.1m (up roughly 10% year over year in constant currency)
• Net Income from Continuing Operations (Q2 2026 vs. Q2 2025): US$11.3m vs. US$4.4m (up 155.3%)
• Adjusted EPS (Earnings Per Share) (Q2 2026 vs. Q2 2025): US$0.60 vs. US$0.41 (up about 45%)
• Non GAAP Gross Margin (Q2 2026 vs. Q2 2025): 46.8% vs. 44.8% (improved by 200 basis points)

Prefer clear visuals instead of scrolling through another wall of earnings tables and footnotes? Get a simple, at-a-glance view of Proto Labs valuation and how the current P/E stacks up in our company report for Proto Labs.

Proto Labs bull story earns partial validation

Bulls argue Proto Labs is shifting from niche prototyping to a production focused, high spec manufacturer riding aerospace, drone and medical demand. Q2 goes a fair way to backing that up. CNC machining grew 13.1% with factory CNC closer to 20% and injection molding rose 12.9%. Management directly links this to aerospace and defense, telecom and data center orders. Aerospace and defense now account for about 25% of revenue with growth near 20%. That aligns with earlier commentary on drone work up very sharply since 2023. The production push also shows up in profitability. Non GAAP gross margin reached 46.8% and adjusted EPS hit US$0.60, the highest since Q3 2020, while cash from operations was US$15.4m with no debt. The medical additive certification story is earlier stage, but added DMLS and MJF capacity in the US points in the direction bulls want.

Bear worries on mix, Europe and durability persist

The bear narrative questions whether Proto Labs can offset structural weaknesses in Europe, legacy services and capital allocation. Q2 does not fully close those gaps. Europe grew revenue 9%, although management still calls it an earnings headwind with profitability a multi quarter fix. That backs the view that international expansion has yet to pull its weight. Network revenue was flat while factory drove growth. That supports concerns that parts of the model, particularly the network, risk stagnation. Additive revenue fell 2.7% with Europe down 6.7%, echoing the earlier warnings about softness in certain service lines. Bears who highlight mixed long term EPS trends and low historical returns on invested capital now face improving margins and cash generation, yet also see continued spend on commercial build out, AI and production capacity. If those investments fail to sustain high single digit to low double digit growth, the risk argument remains alive.

After factory led growth, flat network revenue and softness in additive, it is fair to ask whether Proto Labs is masking deeper structural issues. Review the independent risk analysis for Proto Labs which shows 1 important warning sign to quickly scan hidden vulnerabilities, risk scores and management signals already flagged for you.

Stay Ahead With Proto Labs Insights

If Proto Labs has your attention after this mix of strong margins, aerospace exposure and a 69.3x P/E, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a more comfortable entry point. Once you own Proto Labs or any other stock, use the Portfolio Command Center to keep on top of the key updates that matter and filter out distractions. For a broader view on what other investors are seeing, join the Community and compare different angles on the same data. That way you can identify potential catalysts or risks early and stay a step ahead of the market.

Curious About Alternatives Beyond Proto Labs

Fresh ideas move quickly. Some stocks build quiet momentum, others are dropping back to better entry zones. Check these under the radar for now opportunities before the crowd catches up and get in early.

• Spot resilient compounders early by scanning companies in the list of solid balance sheet and fundamentals stocks (45 results) and see which businesses have the financial strength to keep funding growth when others slow down.
• Ride potential breakout income opportunities by checking the 9 dividend fortresses and focus on cash generative companies that might keep paying out even when sentiment turns cautious.
• Track under followed growth stories by reviewing the 19 high quality undiscovered gems and see which quieter stocks could be drawing attention while valuations still look reasonable.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com